Join
Live feed
·
PRReleasevia Quantisnow
BioLineRx Ltd. logo

BioLineRx Announces FDA Approval of APHEXDA™ (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple Myeloma

ByQuantisnow·Wall Street's wire, on your screen.
BLRX· BioLineRx Ltd.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track BLRX (BioLineRx Ltd.) and more on Quantisnow.